It is crucial to prevent prenatal exposure to teratogenic drugs. With the US Food and Drug Administration Amendments Act in 2007, the US Food and Drug Administration has advised manufacturers to implement Risk Evaluation and Mitigation Strategies to prevent prenatal exposures. Among 12 risk evaluation and mitigation strategy drugs, several had predecessor risk mitigation plans (e.g., isotretinoin), and some were newly required (e.g., mycophenolate).
A recent study characterized the epidemiology of prenatal exposures to definite and potential teratogens during the risk evaluation and mitigation strategy era.
It constructed a time series of pregnancies identified from a national private insurance claims database (IBM MarketScan) to estimate prenatal exposures to teratogenic drugs (2006–2017). It determined pregnancy outcomes, gestational age, and the onset of pregnancy with previously validated algorithms.
The study used The Teratology Information Service and Clinical Pharmacology databases to identify drugs with definite (n=141) or potential (n=65) teratogenic effects and excluded drugs with debatable risks, such as benzodiazepines, statins, tetracyclines, sex hormones, infertility treatments, and gonadotropin-releasing hormone analogs.
This study defined prenatal exposure as ≥1 prescription fill or medical encounter involving the administration of drugs with a definite teratogenic risk (including 12 for which there is a “current or discontinued” risk evaluation and mitigation strategy) or a potential teratogenic risk. It evaluated secular trends and modeled the effects of age, preconception exposure, and state healthcare quality rankings on prenatal exposure, adjusting for demographic factors and clinical conditions.
Thus, Fetuses in more than 1 in 16 pregnancies remained exposed to teratogenic drugs during the past decade. Drugs with Risk Evaluation and Mitigation Strategies caused a small burden of prenatal exposure because of the low background utilization rates and lower pregnancy prevalence among women of childbearing age who used these drugs. Although there are declining exposure rates to teratogenic drugs with definite risks, the rising prenatal exposure to drugs with potential risks needs further assessment. Future research must elucidate the health outcomes of fetuses exposed to potential risk drugs, understand the effectiveness of risk evaluation and mitigation strategy programs, and prioritize teratogenic drugs for advanced risk mitigation.
Sarayani A, Albogami Y, Thai TN, et al. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. American Journal of Obstetrics and Gynecology. 2022;227(2):263.e1-263.e38. https://doi.org/10.1016/j.ajog.2022.01.004.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details